Johnson & Johnson Finds Growth Beyond Legacy Drugs, Lifts 2026 Outlook
Johnson & Johnson (NYSE: JNJ ) on Wednesday reported second-quarter 2026 results that topped Wall Street estimates and raised its full-year sales and adjusted earnings guidance as strength in its Innovative Medicine and MedTech businesses offset continued pressure from several legacy products. Adjusted earnings rose 4.7% year over year to $2.90 per share, beating the analyst consensus estimate of $2.85. Sales increased 6.6% to $25.31 billion, ahead of the consensus estimate of $25.047 billion. Operational sales growth was 5.6%, while adjusted operational growth was 5.7%. Innovative Medicine Driven By Oncology Innovative Medicine sales rose 7.8%, or 6.8% on an operational basis, to $16.38 billion. Growth was driven by oncology drugs Darzalex, Carvykti, Tecvayli and Rybrevant/Lazcluze, along with Tremfya in immunology and Spravato and Caplyta in neuroscience. The gains were partly offse...
Johnson & Johnson (NYSE: JNJ ) on Wednesday reported second-quarter 2026 results that topped Wall Street estimates and raised its full-year sales and adjusted earnings guidance as strength in its Innovative Medicine and MedTech businesses offset continued pressure from several legacy products.
Adjusted earnings rose 4.7% year over year to $2.90 per share, beating the analyst consensus estimate of $2.85.
Sales increased 6.6% to $25.31 billion, ahead of the consensus estimate of $25.047 billion.
Operational sales growth was 5.6%, while adjusted operational growth was 5.7%.
Innovative Medicine Driven By Oncology Innovative Medicine sales rose 7.8%, or 6.8% on an operational basis, to $16.38 billion.
Growth was driven by oncology drugs Darzalex, Carvykti, Tecvayli and Rybrevant/Lazcluze, along with Tremfya in immunology and Spravato and Caplyta in neuroscience.
The gains were partly offset by lower sales of Stelara, which reduced growth by about 760 basis points, as well as declines in Remicade, Imbruvica and Zytiga.
Cancer drug sales climbed 17.3% to $7.41 billion, or 16.1% on an operational basis.
Immunology sales fell 3.7% to $3.84 billion and declined 4.6% operationally.
MedTech Continues To Expand MedTech sales increased 4.5% to $8.93 billion, with operational growth of 3.6%.
The segment benefited from strong demand for wound closure and biosurgery products, electrophysiology devices, Shockwave cardiovascular products, contact lenses and trauma products.
Abiomed sales declined 2% to $440 million, reflecting lower U.S. procedure volumes.
The decline was partly offset by continued international growth, including adoption of the Impella 5.5 heart pump.
Company Raises 2026 Guidance Chairman and Chief Executive Officer Joaquin Duato said the company’s raised outlook and quarterly sales above $25 billion keep it on track to exceed $100 billion in annual revenue for the first time in its 140-year history.
Johnson & Johnson raised its fiscal 2026 adjusted earnings guidance to $11.60-$11.75 per share from the prior range of $11.45-$11.65.
The new outlook is above the analyst consensus estimate of $11.59.
The company also increased its 2026 sales forecast to $100.8 billion-$101.4 billion from $100.3 billion-$101.3 billion.
The updated range compares with the consensus estimate of $101.022 billion.
JNJ Price Action: Johnson & Johnson shares were trading down 0.57% at $252.41 during premarket trading on Wednesday, according to Pro data.
Image via Shutterstock Read Also: Johnson & Johnson Hits Target With IMAAVY In Rare Blood Disorder